All In Biotech

Drug Trial Radar · NCT07568496

Greater Occipital Nerve Block for Migraine With Medication Overuse Headache

Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 130 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

130

Planned (sponsor's estimate)

Start

May 12, 2026

Primary completion

Nov 1, 2028

Study completion Nov 1, 2028

Sponsor

Lead sponsor
Mahidol UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Chiang Mai University, Thailand; Prince of Songkla University; The Royal College of Physicians of Thailand
First posted
May 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Migraine is among the leading causes of disability worldwide. Inappropriate use of acute medications in the setting of primary headache, particularly migraine can result in a debilitating condition known as medication overuse headache (MOH). Treatment of MOH is challenging and the primary therapeutic approach is reducing painkillers which helps decrease the number of headache days. As a part of the detoxification process to discontinue acute medications, bridging therapy is often needed to reduce withdrawal headache. Currently, there are data supporting the use of greater occipital nerve block as a preventive treatment in chronic migraine, but no placebo-controlled trial has evaluated the efficacy of greater occipital nerve block in MOH. Therefore, this research aims to demonstrate the efficacy of greater occipital nerve block in detoxification of migraine patients with MOH. Patients will be recruited from Headache Clinic at 3 centers in Thailand from February 2026 to January 2028. After recruitment, patients will be randomized into 2 groups at a 1:1 ratio using a block of four, namely group A and B. A 5-mL syringe of 2 mL of lidocaine 2% and 2 mL of methylprednisolone 40 mg/mL (80 mg) will be prepared for each patient in group while a 5-mL syringe of 4 mL normal saline will be prepared for each patient in group B. Monthly headache days, duration, severity, acute medication type and number of usage days and relative headache status according to a 5-point Likert scale will be investigated at the 2 weeks, 1st, 2nd and 3rd month, MIDAS at the end of 3rd month.

Conditions

  • Migraine Disorders
  • Medication Overuse Headache
  • Greater Occipital Nerve Block

Interventions

  • Lidocaine 2% and Methylprednisolone 80 mgDrug

    A 4-mL injection containing 2 mL of lidocaine 2% and 2 mL of methylprednisolone 40 mg/mL (80 mg). The injection is administered at the medial third of the distance between the external occipital protuberance and the mastoid process.

  • PlaceboOther

    A 4-mL injection of 0.9% Normal Saline administered at the medial third of the distance between the external occipital protuberance and the mastoid process.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of patients with Medication Overuse Headache (MOH)Time frame: At the end of month 1 and month 3 after detoxification.

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Faculty of Medicine Siriraj Hospital, Mahidol University

    Bangkok, Bangkok, Thailand · Recruiting

  • Faculty of Medicine, Prince of Songkla University

    Hat Yai, Changwat Songkhla, Thailand · Recruiting

  • Faculty of Medicine, Chiang Mai University

    Chiang Mai, Chiang Mai, Thailand · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.